MIRA Pharmaceuticals, Inc.
MIRA
$1.42
-$0.01-0.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.02% | -24.57% | -32.22% | 22.31% | 87.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.99% | -10.05% | -5.96% | 26.69% | 77.75% |
| Operating Income | 18.99% | 10.05% | 5.96% | -26.69% | -77.75% |
| Income Before Tax | 39.26% | 35.93% | 34.46% | -48.99% | -121.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.26% | 35.93% | 34.46% | -48.99% | -121.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.26% | 35.93% | 34.46% | -48.99% | -121.67% |
| EBIT | 18.99% | 10.05% | 5.96% | -26.69% | -77.75% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 45.98% | 42.01% | 38.06% | -58.65% | -151.48% |
| Normalized Basic EPS | 45.95% | 41.99% | 38.05% | -58.71% | -151.57% |
| EPS Diluted | 45.98% | 42.01% | 38.06% | -58.65% | -151.48% |
| Normalized Diluted EPS | 45.95% | 41.99% | 38.05% | -58.71% | -151.57% |
| Average Basic Shares Outstanding | 12.56% | 11.58% | 2.88% | -21.27% | -22.69% |
| Average Diluted Shares Outstanding | 12.56% | 11.58% | 2.88% | -21.27% | -22.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |